'It is the first ever to show antiviral activity against dengue,' Marnix Van Loock, who oversees emerging pathogens research for J&J’s Janssen division, says of the drug
This is AI generated summarization, which may have errors. For context, always refer to the full article.
“It is the first ever to show antiviral activity against dengue,” Marnix Van Loock, who oversees emerging pathogens research for J&J’s Janssen division, said of the drug. In the trial done with Johns Hopkins Bloomberg School of Public Health, 10 volunteers were given a high dose of the J&J pill five days before being injected with a type of dengue. They continued to take the pill for 21 days afterwards.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: